🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07626060
Recruiting Observational

Diagnostic Accuracy of GPT-4o and Claude for HEART Score Calculation in Chest Pain

NCT07626060 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-06
Last updated
2026-06-23

Condition(s) studied

Emergency MedicineArtificial Intelligence (AI)Artificial Intelligence (AI) in DiagnosisChest Pain Rule Out Myocardial Infarction

Investigational drug(s) / intervention(s)

GPT-4o HEART Score CalculatorClaude HEART Score CalculatorThree-Expert Consensus HEART Score

GPT-4o HEART Score Calculator: OpenAI GPT-4o (model: gpt-4o-2024-11-20, temperature=0, max\_tokens=500, response\_format=JSON). Each patient's anonymized anamnesis text, ECG report text, troponin value, and age are submitted via a separate API call with no conversation history. Output: HEART score components (0-2 each), total score (0-10), risk group, and indeterminate status.

Claude HEART Score Calculator: Anthropic Claude (model: claude-sonnet-4-6, temperature=0, max\_tokens=500, response\_format=JSON). Identical system prompt and input format as GPT-4o. Processed independently with no cross-contamination between models. Output: same JSON schema as GPT-4o.

Three-Expert Consensus HEART Score: Three emergency medicine physicians (\>=3 years experience, HEART-score trained) independently score each anonymized record. Majority vote (2/3) determines component scores; a 4th adjudicator resolves ties. Experts are blinded to LLM scores, each other's scores, and MACE outcomes.

Study summary

This prospective observational diagnostic accuracy study evaluates whether large language models (LLMs) - GPT-4o (OpenAI, gpt-4o-2024-11-20) and Claude (Anthropic, claude-sonnet-4-6) - can accurately calculate HEART scores from unstructured Turkish clinical notes and predict 30-day major adverse cardiac events (MACE) in emergency department patients presenting with non-traumatic chest pain.

The study will enroll 600 consecutive adult patients. For each patient, the same anonymized data (free-text anamnesis, ECG report text, troponin value, and age) will be independently processed by both LLMs via separate API calls with deterministic settings (temperature=0, JSON format). A three-expert consensus HEART score - derived through blinded independent scoring by three emergency medicine physicians with majority-vote adjudication - serves as the reference standard for agreement analysis. Actual 30-day MACE (all-cause death, AMI Type 1/2/4b, unplanned revascularization) determined via national health database and telephone follow-up serves as the outcome for diagnostic accuracy analysis.

A secondary documentation-quality sub-study will quantify how spontaneously Turkish emergency anamnesis notes capture HEART score parameters.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
INCLUSION CRITERIA: * Age \>=18 years * Chief complaint of non-traumatic chest pain at the emergency department * Written informed consent obtained from the patient or legally authorized representative * Availability for 30-day follow-up (reachable by telephone and/or actively registered in the e-Nabiz national health database) EXCLUSION CRITERIA: * Traumatic chest pain etiology * ST-elevation myocardial infarction (STEMI) at presentation requiring immediate reperfusion protocol * Refusal or subsequent withdrawal of informed consent * Inability to complete the mandatory 30-day follow-up period WITHDRAWAL CRITERIA: * Patient or representative requests data withdrawal after initial consent * Administrative identification of retrospective data entry after enrollment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Marmara University Pendik Training and Research Hospital Istanbul Istanbul Recruiting

More Marmara University Pendik Training and Research Hospital trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07626060 on ClinicalTrials.gov ↗ ← All trials in Turkey